Date: 2014-09-22
Type of information: Establishment of a new subsidiary in the EU
Compound: immunotherapy platform TABs (T-cell-specific AntiBodies)
Company: MediGene (Germany) Trianta Immunotherapies (Germany) Max Delbrück Center for Molecular Medicine (MDC) (Germany) Helmholtz Zentrum München - German Research Center for Environmental Health, Munich (HMGU) (Germany)
Therapeutic area: Autoimmune diseases - Cancer - Oncology
Type agreement:
Action mechanism: The TABs immunotherapy platform serves to generate monoclonal antibodies which recognise different T cells based on their T cell receptors (TABs = T cell-specific antibodies). These TABs are intended to remove unwanted cells from the body in order to treat T cell-induced diseases such as T cell leukaemia or various autoimmune diseases. Monoclonal antibodies which are able to distinguish between different T cell receptors have already been produced and characterised. Proof of technology was established in preclinical experiments.
Disease:
Details: * On September 22, 2014, Medigene announce that its subsidiary Trianta Immunotherapies GmbH entered two new research collaborations for further development of its immunotherapy platform TABs (T-cell-specific AntiBodies) for the treatment of various types of cancer and autoimmune diseases. In the future, scientists of the Max Delbrück Center for Molecular Medicine (MDC) and the Helmholtz Zentrum München - German Research Center for Environmental Health, Munich (HMGU) will undertake single research and development tasks in this special field.
Preclinical in vivo data about the treatment of autoimmune diseases and T cell leukemia with monoclonal antibodies generated during the granted period will be of great value for further clinical development of this immunotherapy platform. Overall, the collaboration with both research institutions offers Medigene extended scientific synergies regarding technology transfer, infrastructure and exchange of knowledge.
Additionally, Trianta will receive increased public funding for its immunotherapy platform TABs. The grant which has already been awarded by the Federal Ministry of Education and Research, (Bundesministerium für Bildung und Forschung = BMBF) within the scope of the \"m4 - Personalized Medicine and Targeted Therapies: a new Dimension of Drug Development\" Munich Leading-Edge Cluster initiative in beginning of June, now has been increased. The sponsored project intends to provide evidence of the elimination of pathogenic T cells in T-cell leukemia and autoimmune diseases, applying in-vivo and in-vitro methods with T-cell receptor-specific monoclonal antibodies. The project is financed by Medigene (60%) as well as the BMBF grant (40%). The project is funded by the program \'m4 - Personalised Medicine and Targeted Therapies\' for which the Munich Biotech Cluster was awarded \'Leading-Edge cluster status\' by the German Federal Ministry of Research and Education (BMBF) in 2010. For a 5 year period, the program is funded with € 40 million from the BMBF, which are complemented by EUR 40 million from the participating companies in more than 50 cooperative R&D projects from industry and scientific institutions.
Financial terms:
Latest news:
